Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia

The BTK inhibitor ibrutinib is a highly effective, new targeted therapy for chronic lymphocytic leukemia (CLL) that thwarts leukemia cell survival, growth, and tissue homing. The effects of ibrutinib treatment on the T cell compartment, which is clonally expanded and thought to support the growth of...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunol
Autori principali: Yin, Qingsong, Sivina, Mariela, Robins, Harlan, Yusko, Erik, Vignali, Marissa, O’Brien, Susan, Keating, Michael J., Ferrajoli, Alessandra, Estrov, Zeev, Jain, Nitin, Wierda, William G., Burger, Jan A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5296363/
https://ncbi.nlm.nih.gov/pubmed/28077600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1601190
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi